Previous 10 | Next 10 |
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that i...
Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances PR Newswire ˗ REZLIDHIA induced durable remissions in adult patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , Feb. 2, 2023 /PRNewswir...
Stocks with share prices under $5 (aka " penny stocks ") are typically too risky to consider. The current economic environment, however, has pushed several intriguing, innovation-oriented companies into penny stock territory. Which beaten-down innovation stocks are worth checking out righ...
Palm Beach, FL – January 19, 2023 – FinancialNewsMedia.com News Commentary – Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T cell-based immunotherapy has greatly revolutionized the par...
National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 18, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, ...
Rigel Pharmaceuticals ( NASDAQ: RIGL ) reported preliminary Q4 total revenue of about $51.3M, well ahead of analysts estimate of $21.65M. ( RIGL ) is up 5.6% before the bell. The Q4 total revenue includes Tavalisse preliminary net product sales of about $21.9M and Rezl...
Summary In terms of product sales, RIGL has been a one drug company with Tavalisse in immune thrombocytopenia. The recent approval of Rezlidhia opens the door for investors to track the growth of another drug, a new source of excitement. The potential for sales growth with Tavalisse...
Cancer-focused biotech Rigel Pharmaceuticals ( NASDAQ: RIGL ) announced Thursday the U.S. availability of its oral therapy Rezlidhia for adults with relapsed or refractory (R/R) acute myeloid leukemia (AML). The launch comes days after the FDA approval of Rezlidhia early this month. ...
Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation PR Newswire SOUTH SAN FRANCISCO, Calif. , Dec. 22, 2022 /PRNewswir...
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes PR Newswire R289 is an investigational, oral, inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being studied as a potentially differentiated app...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...